Implementing Keytruda/Pembrolizumab Testing in Clinical Practice

This Commentary addresses the FDA approval of pembrolizumab and the changes necessary in clinical practice to identify patients who would benefit from such treatment.

Detalles Bibliográficos
Autores principales: Ratner, Dmitry, Lennerz, Jochen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067935/
https://www.ncbi.nlm.nih.gov/pubmed/29523645
http://dx.doi.org/10.1634/theoncologist.2017-0591
Descripción
Sumario:This Commentary addresses the FDA approval of pembrolizumab and the changes necessary in clinical practice to identify patients who would benefit from such treatment.

Ejemplares similares